Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma

Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma

In this study, we aimed to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) treatment for unresectable hepatocellular carcinoma (HCC) and to analyze the factors affecting overall survival (OS). A total of 69 patients who received Atez/Bev at our institutions for unresecta...

Full description

Bibliographic Details
Main Authors: Shinji Unome, Kenji Imai, Koji Takai, Takao Miwa, Tatsunori Hanai, Yoichi Nishigaki, Hideki Hayashi, Takahiro Kochi, Shogo Shimizu, Junji Nagano, Soichi Iritani, Atsushi Suetsugu, Masahito Shimizu
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
hepatocellular carcinoma
atezolizumab
bevacizumab
prognosis factor
ALBI score
PIVKA-II
Online Access:https://www.mdpi.com/2072-6694/14/24/6089

Internet

https://www.mdpi.com/2072-6694/14/24/6089

Similar Items